Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients
- Conditions
- Acute Heart Failure
- Registration Number
- NCT01264159
- Lead Sponsor
- Hillel Yaffe Medical Center
- Brief Summary
It is well known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedence-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 70
- Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure during their hospitalization
- Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Prevention of acute heart failure development in acute MI patients Three years
- Secondary Outcome Measures
Name Time Method Improvement of clinical outcome in patients with lung impedence-guided treatments Three years
Trial Locations
- Locations (1)
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel
Hillel Yaffe Medical Center🇮🇱Hadera, Israel